Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
💎 Access the Market Tools Trusted by Thousands of Investors Get Started
Drugmakers' shares stabilise after Zantac litigation slump
Published Aug 12, 2022 04:24AM ET
Updated Aug 12, 2022 02:26PM ET
© Reuters. FILE PHOTO: Zantac heartburn pills are seen in this picture illustration taken October 1, 2019. REUTERS/Brendan McDermid/Illustration/File Photo
By Natalie Grover
LONDON (Reuters) - Shares in GSK, Sanofi (NASDAQ:SNY), Haleon and Pfizer (NYSE:PFE) began to recover on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.
The companies' share prices had fallen sharply this week on investor concern about the litigation over potential cancer-causing impurities that prompted the drug's withdrawal from markets in 2019 and 2020.
More than 2,000 Zantac-related legal cases have been filed in the United States, analysts say, with the first trial beginning this month.
The prospect of impending Zantac litigation is not new. Among other disclosures, recently listed Haleon had highlighted the risk of such lawsuits in its prospectus.
GSK, Sanofi, Pfizer and Haleon have lost a combined $39 billion from their market value over the past week in the absence of any other particular catalyst, Barclays (LON:BARC) analysts wrote in a note on Friday.
Since the start of the week GSK's shares had fallen 16% by Thursday's close while Sanofi lost 13.1%, Haleon 13.7% and Pfizer 2%.
Zantac, originally marketed by a forerunner of GSK, has been sold by several companies since the loss of patent exclusivity in the late 1990s, including Pfizer, Boehringer Ingelheim and Sanofi.
Haleon, spun out as an independent company last month, comprises consumer health assets once owned by GSK and Pfizer.
Uncertainty over the outcome of litigation has sparked fears of a worse-case scenario where costs run into billions of dollars, as happened in cases involving Merck & Co's painkiller Vioxx and Bayer (OTC:BAYRY)'s glyphosate-based weedkiller.
Pharma investors' most recent memory of legal risk is the experience with Bayer, Barclays analysts said, adding that the company's shares have underperformed the European healthcare sector by about 80% since the first so-called bellwether case went against Bayer in 2018.
"As such, the seeming market reaction of 'sell first; ask questions later' makes some sense," the analysts wrote.
On Friday morning GSK shares rose 3.7%, Sanofi gained 1% and Haleon was up 1.7%. Pfizer, meanwhile, edged 0.4% higher in U.S. pre-market trading.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.